The measurement of neurofilament light chain (NfL) levels is emerging as a promising biomarker for the monitoring and management of neurodegenerative diseases, such as Alzheimer’s disease, MS, and Parkinson’s disease. The gene discussed is NEFL; the disease is early-onset autosomal dominant Alzheimer disease.